Complete Story
03/28/2017
The FDA has approved ZEJULA (niraparib) for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
The FDA has approved ZEJULA (niraparib), a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
For more information, click here.
Report Broken Links
Have you encountered a problem with a URL (link) on this page not working or displaying an error message? Help us fix it!